In Brief: Quigley
This article was originally published in The Tan Sheet
Executive Summary
Quigley: Purchase orders for Cold-Eeze zinc lozenges have reached $12.5 mil., the Doylestown, Penn. firm states Jan. 15. The manufacturer of the homeopathic cold product had announced a $3.5 mil. backlog in December, noting at the time its plans for expansion of its manufacturing facilities ("The Tan Sheet" Dec. 9, 1996, In Brief). With its increased manufacturing capacity, Quigley plans to produce around $1.5 mil. of Cold-Eeze per week. The company recently announced an anticipated $3.9 mil. in revenues and net earnings of $1.8 mil. for the first quarter ended Dec. 31. For the fiscal year ended Sept. 30, Quigley reported revenues of $1 mil. and a loss of $694,269, compared to $501,903 in revenues and a $152,556 loss in the previous fiscal year. Also, Quigley announced Jan. 17 that it has requested an investigation by the Securities & Exchange Commission into "attempts to discredit the company through fake press releases to the media and incorrect information posted on the Internet"...